Загрузка...
ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
BACKGROUND: ROS1 rearrangements are validated drivers in lung cancer, which have been identified in a small subset (1–2%) of patients with non-small cell lung cancer (NSCLC). To date, 18 fusion genes of ROS1 have been identified in NSCLC. The ALK inhibitor (crizotinib) exhibits therapeutic effect ag...
Сохранить в:
| Опубликовано в: : | BMC Cancer |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6683537/ https://ncbi.nlm.nih.gov/pubmed/31382924 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5948-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|